TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04217902

Intervention type: OTHER
Intervention: Description of patients' experiences of diabetes care delivery and planning
Description: Semi-directed interviews will be conducted with people living with type 1 or type 2 diabetes in person or by phone to assess and describe the care delivery pathway they have been through. Information on 3 domains will be assessed: clinical (information they consider essential for health care professionals to systematically have access to during consultations and other health-related interventions such as therapeutic education sessions), technological (what kind of digital services and technologies they use or are willing to use), and behavioural (the decision-making process and the key interactions that build the care delivery pathway).

Intervention type: OTHER
Intervention: Description of health care professionals needs and experiences in diabetes care delivery and planning
Description: Semi-directed interviews will be conducted with health care professionals working in diabetes care in person or by phone to assess and describe their needs and experiences in diabetes care. Information on 3 domains will be assessed: clinical (the information they consider to be essential to inform decisions in diabetes care, where and if they currently find that information and problems they might encounter), technological (which software they currently use and how data is input into clinical information systems), and behavioural (how care coordination is currently managed, how interactions with patients and other professionals are undertaken).
Study: NCT06403267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NoNO-42
Description: a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml 0.9% normal Saline
Study: NCT05076682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline
Description: Choline 300mg tid or 500mg bid, p.o

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody and chemotherapy
Description: PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody and chemotherapy
Description: PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody and chemotherapy
Description: PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Cromoglicate
Description: Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
Study: NCT04975789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: InfoViz
Description: The pain InfoViz tool is a two-page paper tool that consists of an explanation of how to use the tool in both Hmong and English, a culturally-appropriate Faces pain severity scale, pain body diagram, and 13 pain qualities in the form of icons representing each pain quality metaphor. The interpreter explains the instructions in Hmong, then marks the body areas corresponding to the location of pain reported by the participant, and marks the pain qualities expressed by the metaphors selected by the Hmong patient. In the clinic appointment, the interpreter communicates to the physician, in English, the pain location and qualities identified by the participant, using the medical terms identified on the InfoViz tool.
Study: NCT05173051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solid Medication intake vs. crushed medication intake
Description: The swallowing ability for solid and crushed medications in stroke patients is evaluated.
Study: NCT05076682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz 600mg qd, p.o
Study: NCT06348576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2091
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-209 Placebo
Description: PO, Once daily(QD), 8weeks
Study: NCT04721509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental : Smartphone-based telemedicine with the app 'Songaree diabetes'
Description: Experimental group: outpatient clinic and offline education every 12 weeks plus telemedicine and education with smartphone app 'Songaree diabetes' every 2 weeks for 24 weeks
Study: NCT05036694

Intervention type: DEVICE
Group type: OTHER
Intervention: FUJILAM KIT
Description: Urine based test to detect LAM
Study: NCT04941716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study: NCT06348576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2091 Placebo
Description: PO, Once daily(QD), 8weeks
Study: NCT06217432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training for knee extensors
Description: The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training for knee extensors
Description: The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
Study: NCT04941716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06485518

Intervention type: BEHAVIORAL
Intervention: The 5G RHS group receiving audio-video conferencing and effective data management for decision-making via augmented reality platform RealHealthcare System.
Description: The 5G RHS group will receive audio-video conferencing and effective data management for decision-making via augmented reality platform. A total of 14 physicians from SRRSH will be participated in the study, offering remote consultations and instant guidance to the physician.
Study: NCT05828784

Intervention type: DEVICE
Group type: OTHER
Intervention: Intersomatic arthrodesis
Description: Arthrodesis is an operative modality also used in the treatment of multiple recurrences of herniated discs, stenosis (narrowing) of the spinal anal, degenerative and malformative spondylolisthesis.~The procedure can be performed with different surgical techniques, but in all cases it aims to achieve the same goal: to re-establish, through the use of spacers, the correct distance between two vertebral somes, in cases of disc degeneration, that are no longer able to fulfill their function; that is, they no longer absorb mechanical stresses and/or compress the nerve structures of the spine causing almost always unbearable (disabling) pain.
Study: NCT04821999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a 940-nm diode laser
Description: a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.
Study: NCT05389358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asiphephe health worker training
Description: Lay health workers are already employed by the Department of Health and are trained in-service (30 hours) and receive monthly supervision (total of approximately 6 one-on-one hours; 15 group hours).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asiphephe therapeutic sessions
Description: Asiphephe sessions are manualized using illustrated job aids, a participant workbook, session checklists, and an intervention manual. The model is informed by problem-solving therapy (Lund, 2018), trauma-informed coping (Sikkema, 2018) and safety planning (Garcia-Moreno, forthcoming) and was piloted with 12 health workers with input from 3 global mental health experts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPV assessment
Description: IPV intensity as measured by WHO Multicountry Study Instrument at a cut-off of any past-year physical/sexual/psychological violence exposure vs. none

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPV assessment
Description: IPV intensity as measured by WHO Multicountry Study Instrument at a cut-off of any past-year physical/sexual/psychological violence exposure vs. none

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral for IPV or Mental Health
Description: Study staff are trained to recognize signs or symptoms of distress and to make appropriate referrals to appropriate community-based services, if necessary. Experienced mental health professionals on the investigative can be consulted or referred to should a participant exhibit severe symptom of mental distress.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral for IPV or Mental Health
Description: Study staff are trained to recognize signs or symptoms of distress and to make appropriate referrals to appropriate community-based services, if necessary. Experienced mental health professionals on the investigative can be consulted or referred to should a participant exhibit severe symptom of mental distress.
Study: NCT05361746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Plus Adhesive
Description: Eligible teeth with Class-V NCCLs randomized to the SBU+ treatment group will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive using total-etch mode and Filtek Universal Restorative material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scotchbond Universal Adhesive
Description: Eligible teeth with Class-V NCCLs randomized to the SBU Control group will undergo restoration(s) using Scotchbond Universal Plus (SBU) Adhesive using total-etch mode and Filtek Universal Restorative material.
Study: NCT05584657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem etzadroxil/probenecid
Description: Oral sulopenem twice daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanate
Description: Oral Augmentin twice daily for 5 days
Study: NCT05070650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: 200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
Study: NCT05477641

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block
Description: Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule
Study: NCT04850040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: 250 mg, oral every other day. Approximately half an hour after a meal (the daily dose should be taken at the same time as possible) with warm boiled water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200 mg, 30 minutes intravenous drip (overall dosing time no shorter than 20 minutes and no longer than 60 minutes, including tube flush time) once every 2 weeks, with the first dose administered concurrently with Apatinib Mesylate Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, once every 2 weeks, to be administered half an hour after Camrelizumab injection.
Study: NCT06435195

Intervention type: PROCEDURE
Intervention: Surgical Removal
Description: Resection of pituitary pathologies.

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis
Study: NCT05900414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic patient decision aid
Description: Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Link to website with information about atrial fibrillation treatments
Study: NCT05272059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHS552
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
Study: NCT05070650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 500 mg/10 mg granules for oral solution: one sachet three times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 500 mg/10 mg granules for oral solution: one sachet three times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: 500 mg/10 mg granules for oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 500 mg/10 mg granules for oral solution
Study: NCT06569290

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primer postcard
Description: Inclusion of a mailed primer post card

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primer postcard
Description: Inclusion of a mailed primer post card

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primer postcard
Description: Inclusion of a mailed primer post card

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primer postcard
Description: Inclusion of a mailed primer post card

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control recruitment letter
Description: a recruitment letter without any behaviorally-informed language

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control recruitment letter
Description: a recruitment letter without any behaviorally-informed language

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control recruitment letter
Description: a recruitment letter without any behaviorally-informed language
Study: NCT05592808

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Description: Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Description: Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Description: Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Dye Taping
Description: After ESWT application, Low-Dye Taping will be applied 3 times, once a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: After ESWT application, Kinesio Taping will be applied 3 times, once a week.
Study: NCT05810636

Intervention type: DEVICE
Intervention: Garmin Vivosmart wearable device
Description: Wearing smartwatches to collect data

Intervention type: DEVICE
Intervention: Garmin Vivosmart wearable device
Description: Wearing smartwatches to collect data
Study: NCT06569290

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control recruitment letter
Description: a recruitment letter without any behaviorally-informed language

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral theory-informed recruitment letter (prospect theory)
Description: the recruitment letter will use prospect theory and deliver a low risk, gain-framed behaviorally-informed message.
Study: NCT05272059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHS552
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHS552
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHS552
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
Study: NCT05106972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-MSC infusion
Description: UC-MSC infusion by introvenus
Study: NCT05137522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combines with VP-16 and methylprednisolone
Description: Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
Study: NCT06252610

Intervention type: DRUG
Intervention: Radiotracer Injection
Description: An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~* 6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded;~* The catheter will be flushed with 0.9% saline solution;~* The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably.

Intervention type: DRUG
Intervention: Contrast Media, Magnetic Resonance
Description: The same intravenous catheter used to inject the radiotracer will be used to inject the hepatospecific gadolinium contrast agent Eovist (Bayer, Whippany, NJ);~* After being positioned on the PET/MRI table, the nuclear medicine technologist will connect the patient to the MRI-safe power injector;~* The catheter will be flushed before and after injection with 0.9% saline solution;~* About halfway through the imaging session, the study staff will inform the patient that they are going to be administering the contrast agent and what sensations they should and should not expect;~* The contrast will then be injected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired When necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes
Study: NCT04869579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium (as Selenious Acid)
Description: Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Active comparator arm participants will receive the standard of care therapy plus a Saline-based placebo.
Study: NCT04772365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819
Description: SHR-1819 will be subcutaneously administered with different dose levels;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be subcutaneously administered with different dose levels;
Study: NCT05477641

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block
Description: Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca Compartment Block
Description: Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca Compartment Block
Description: Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.
Study: NCT06569290

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral theory-informed recruitment letter (prospect theory)
Description: the recruitment letter will use prospect theory and deliver a low risk, gain-framed behaviorally-informed message.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral theory-informed recruitment letter (prospect theory)
Description: the recruitment letter will use prospect theory and deliver a low risk, gain-framed behaviorally-informed message.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral theory-informed recruitment letter (prospect theory)
Description: the recruitment letter will use prospect theory and deliver a low risk, gain-framed behaviorally-informed message.